Department of Pharmacy, Nimes University Hospital, France.
Department of Biostatistics, Epidemiology, Public Health, and Innovation in Methodology (BESPIM), CHU Nîmes, Montpellier University, Nîmes, France; VBIC, INSERM U1047, Montpellier University, Department of Microbiology and Hospital Hygiene, Nimes University Hospital, France.
Int J Antimicrob Agents. 2023 May;61(5):106768. doi: 10.1016/j.ijantimicag.2023.106768. Epub 2023 Mar 4.
The aim of this study was to determine the correlation between antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in Escherichia coli at a hospital level, and assess the capacity of dynamic regression (DR) models to predict AMR for their use in deployment of antimicrobial stewardship programs (ASPs).
A retrospective epidemiological study was conducted in a French tertiary hospital between 2014 and 2019. DR models were used to assess the correlation between AMC and AMR from 2014 to 2018. The predictive abilities of the models were estimated by comparing the predicted data with those observed in 2019.
Rates of fluoroquinolone and cephalosporin resistance decreased. AMC increased overall but decreased for fluoroquinolone. DR models highlighted that the decrease in use of fluoroquinolone and the increase in use of anti-pseudomonal activity penicillin with beta-lactamase inhibitor (AAPBI) explained 54% of the decrease in fluoroquinolone resistance and 15% of the decrease in cephalosporin resistance. In addition, penicillin/beta-lactamase inhibitor (PBI) consumption explained 53% of PBI resistance, and beta-lactam use explained 36% of penicillin resistance, with both remaining stable over time. DR models had predictive capabilities with margins of error from 8% to 34%.
Over a six-year period in a French tertiary hospital, decreasing rates of resistance to fluoroquinolones and cephalosporins were correlated with decreasing use of fluoroquinolone and increasing use of AAPBI, whereas rates of resistance to penicillin remained high and stable. The results indicate that DR models should be used with caution for AMR forecasting and ASP implementation.
本研究旨在确定医院层面大肠埃希菌的抗菌药物消耗(AMC)与抗菌药物耐药性(AMR)之间的相关性,并评估动态回归(DR)模型预测 AMR 的能力,以便将其用于部署抗菌药物管理计划(ASPs)。
本回顾性流行病学研究于 2014 年至 2019 年在法国一家三级医院进行。DR 模型用于评估 2014 年至 2018 年期间 AMC 与 AMR 之间的相关性。通过比较 2019 年观察到的数据与模型预测的数据,评估模型的预测能力。
氟喹诺酮类和头孢菌素类耐药率下降。总体上 AMC 增加,但氟喹诺酮类减少。DR 模型表明,氟喹诺酮类药物使用减少和抗假单胞菌活性青霉素与β-内酰胺酶抑制剂(AAPBI)使用增加,解释了氟喹诺酮类耐药率下降的 54%和头孢菌素类耐药率下降的 15%。此外,青霉素/β-内酰胺酶抑制剂(PBI)消耗解释了 PBI 耐药率的 53%,β-内酰胺类药物使用解释了青霉素耐药率的 36%,这两种耐药率随着时间的推移保持稳定。DR 模型具有预测能力,误差幅度为 8%至 34%。
在法国一家三级医院的六年期间,氟喹诺酮类和头孢菌素类耐药率的下降与氟喹诺酮类药物使用的减少和 AAPBI 的增加相关,而青霉素耐药率仍然较高且稳定。结果表明,DR 模型在预测 AMR 和实施 ASP 时应谨慎使用。